Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
OptiBiotix HealthSTU:OB3 Receivables Turnover is 2.32 as of Dec. 2025. The stock has 4 warning signs investors should review. Among 841 Biotechnology companies, OptiBiotix Health ranks worse than 61.24% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. OptiBiotix Health's Revenue for the
six
months ended in Dec. 2025 was €0.70 Mil. OptiBiotix Health's average Accounts Receivable for the
six
months ended in Dec. 2025 was €0.30 Mil.
Hence, OptiBiotix Health's Receivables Turnover for the
six
months ended in Dec. 2025 was 2.32.
OptiBiotix Health (STU:OB3) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
OptiBiotix Health Receivables Turnover Related Terms
OptiBiotix Health Receivables Turnover Historical Data
* Premium members only.
The historical data trend for OptiBiotix Health's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:OB3 vs VRTX, REGN, ALNY: Receivables Turnover Comparison
For the Biotechnology subindustry, OptiBiotix Health's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
OptiBiotix Health Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, OptiBiotix Health's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where OptiBiotix Health's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OptiBiotix Health (STU:OB3) has a Receivables Turnover of 2.32 as of Dec. 2025. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on OptiBiotix Health and its competitors. According to the industry distribution chart, OptiBiotix Health ranks #515 out of 841 companies in the Biotechnology industry, placing it in the top 61.2%.
Is OptiBiotix Health's Receivables Turnover too high?
OptiBiotix Health's current Receivables Turnover is 2.32. The Biotechnology industry median Receivables Turnover is 5.28. OptiBiotix Health's value of 2.32 is 56.1% below this industry median. Based on the distribution chart, OptiBiotix Health ranks #515 out of 841 companies in the Biotechnology industry, which is below the industry midpoint.
How does OptiBiotix Health's Receivables Turnover compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, OptiBiotix Health ranks #515 out of 841 companies for Receivables Turnover. This places OptiBiotix Health in the lower half of its industry. The industry median Receivables Turnover is 5.28. OptiBiotix Health's value of 2.32 is 56.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.28, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. OptiBiotix Health's current Receivables Turnover of 2.32 is 56.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on OptiBiotix Health and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. OptiBiotix Health's current Receivables Turnover is 2.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OptiBiotix Health stock overvalued right now?
OptiBiotix Health (STU:OB3) has a current Receivables Turnover of 2.32. The stock's GF Value™ is €0.34, compared to a current price of €0.06 — trading 81.5% below its estimated fair value. The current Receivables Turnover is 2.32 and 56.1% below the Biotechnology industry median of 5.28. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For OptiBiotix Health (STU:OB3), the current Receivables Turnover is 2.32 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
OptiBiotix Health PLC principal activity is that of identifying and developing microbial strains, compounds, and formulations for use in food ingredients, supplements and active compounds that can impact on human physiology, deriving potential health benefits. It is a life sciences business focused on the development of products which reduce hunger and food cravings, enhance the gut microbiome, and provide a healthy substitute for sugar. Its product portfolio includes First-generation products- SlimBiome, WellBiome; and Second-generation solutions- SweetBiotix, Microbiome Modulators. The group has one class of business. It has presence in United Kingdom, United States, India China, and Rest of world. The company generates majority of revenue from United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:OB3 has been successfully added to your 
